Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B Kimball

Showing results (261-270 of 373) with videos related to

Pageof 38
Sort By:
Journal of the European Academy of Dermatology and Venereology : JEADV|June 22, 2010
Economic burden of comorbidities in patients with psoriasis is substantialA B Kimball, A Guérin, M Tsaneva, et al.
The British Journal of Dermatology|April 2, 2014
Demography, baseline disease characteristics and treatment history of patients with psoriasis enrolled in a multicentre, prospective, disease-based registry (PSOLAR)A B Kimball, C Leonardi, M Stahle, et al.
The British Journal of Dermatology|October 2, 2013
Impact of brodalumab treatment on psoriasis symptoms and health-related quality of life: use of a novel patient-reported outcome measure, the Psoriasis Symptom InventoryK B Gordon, A B Kimball, D Chau, et al.
The British Journal of Dermatology|March 28, 2019
Assessment of the effects of immunogenicity on the pharmacokinetics, efficacy and safety of tildrakizumabA B Kimball, T Kerbusch, F van Aarle, et al.
Journal of the American Academy of Dermatology|January 7, 2017
Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trialAndrew Blauvelt, Kim A Papp, Christopher E M Griffiths, et al.
Journal of Drugs in Dermatology : JDD|August 21, 2018
Long-Term Efficacy of Guselkumab for the Treatment of Moderate-to-Severe Psoriasis: Results from the Phase 3 VOYAGE 1 Trial Through Two YearsChristopher E M Griffiths, Kim A Papp, Alexa B Kimball, et al.
The Journal of Dermatological Treatment|September 22, 2021
Pregnancy outcomes in patients with psoriasis, psoriatic arthritis, or axial spondyloarthritis receiving ixekizumabA Egeberg, L Iversen, A B Kimball, et al.
Journal of the American Academy of Dermatology|August 22, 2023
Wound care for patients with hidradenitis suppurativa: Recommendations of an international panel of expertsDivya Chopra, Nimay Anand, Shandi Brito, et al.
Archives of Dermatology|July 23, 2008
US dermatology residents' satisfaction with training and mentoring: survey results from the 2005 and 2006 Las Vegas Dermatology SeminarsScott R Freeman, Riley E Greene, Alexa B Kimball, et al.
The American Journal of Cardiology|May 1, 1985
Effect of intracoronary nitroglycerin on myocardial blood flow and distribution in pacing-induced angina pectoris. Quantitative assessment by single-photon emission tomographyP Liu, S Houle, R J Burns, et al.
Pageof 38

Showing results (261-270 of 373) with videos related to

Sort By:
Pageof 38
Journal of the European Academy of Dermatology and Venereology : JEADV|June 22, 2010
Economic burden of comorbidities in patients with psoriasis is substantialA B Kimball, A Guérin, M Tsaneva, et al.
The British Journal of Dermatology|April 2, 2014
Demography, baseline disease characteristics and treatment history of patients with psoriasis enrolled in a multicentre, prospective, disease-based registry (PSOLAR)A B Kimball, C Leonardi, M Stahle, et al.
The British Journal of Dermatology|October 2, 2013
Impact of brodalumab treatment on psoriasis symptoms and health-related quality of life: use of a novel patient-reported outcome measure, the Psoriasis Symptom InventoryK B Gordon, A B Kimball, D Chau, et al.
The British Journal of Dermatology|March 28, 2019
Assessment of the effects of immunogenicity on the pharmacokinetics, efficacy and safety of tildrakizumabA B Kimball, T Kerbusch, F van Aarle, et al.
Journal of the American Academy of Dermatology|January 7, 2017
Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trialAndrew Blauvelt, Kim A Papp, Christopher E M Griffiths, et al.
Journal of Drugs in Dermatology : JDD|August 21, 2018
Long-Term Efficacy of Guselkumab for the Treatment of Moderate-to-Severe Psoriasis: Results from the Phase 3 VOYAGE 1 Trial Through Two YearsChristopher E M Griffiths, Kim A Papp, Alexa B Kimball, et al.
The Journal of Dermatological Treatment|September 22, 2021
Pregnancy outcomes in patients with psoriasis, psoriatic arthritis, or axial spondyloarthritis receiving ixekizumabA Egeberg, L Iversen, A B Kimball, et al.
Journal of the American Academy of Dermatology|August 22, 2023
Wound care for patients with hidradenitis suppurativa: Recommendations of an international panel of expertsDivya Chopra, Nimay Anand, Shandi Brito, et al.
Archives of Dermatology|July 23, 2008
US dermatology residents' satisfaction with training and mentoring: survey results from the 2005 and 2006 Las Vegas Dermatology SeminarsScott R Freeman, Riley E Greene, Alexa B Kimball, et al.
The American Journal of Cardiology|May 1, 1985
Effect of intracoronary nitroglycerin on myocardial blood flow and distribution in pacing-induced angina pectoris. Quantitative assessment by single-photon emission tomographyP Liu, S Houle, R J Burns, et al.
Pageof 38